Trip.com analysis: As off-season demand continues to grow Is there such a thing as an off-season in the post pandemic world
SINGAPORE, Nov. 17, 2022 /PRNewswire/ — Analysis of recent Trip.com data leads us to question whether on and off-season travel is becoming a thing of the past following the pandemic. Increased demand for overseas travel, coupled with more flexible work schedules in remote working environments, appears to be producing a trend towards year-round demand to many […]
Mia Wray Announces New EP ‘Stay Awake’ and Tour, Shares Title Track
Melbourne singer-songwriter Mia Wray has announced her EP, Stay Awake, will arrive next year. The EP, set to arrive Friday, 10th February via Ivy League Records, has been previewed with two singles thus far this year – ‘Rerun’ in March and ‘Evidence’ in August – and follows a string of standalone singles such as ‘Work for Me’ […]
Artist on Artist: Ra Ra Viper Grill Their Tour Pals From The Velvet Club
Fremantle indie rock crew Ra Ra Viper are capping off the year with a national tour, including shows in Melbourne, Sydney, Newcastle and Wollongong, as well as a trio of headliners at their North Freo local, Mojos. Melbourne indie rock quintet The Velvet Club are joining Ra Ra Viper throughout the run, fresh off their […]
Ascletis Announces IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors by China NMPA
–While the ASC61 Phase I study is ongoing in the U.S., the Investigational New Drug (IND) approval in China will accelerate the global development of ASC61, an in-house developed oral PD-L1 small molecule inhibitor HANGZHOU and SHAOXING, China, Nov. 17, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the approval of the […]
RemeGen’s Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ — RemeGen Co., Ltd. (“RemeGen” or “the Company”) (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced on November 5 that the Company’s self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been officially included in the newly released Chinese Society of Clinical Oncology (CSCO) 2022 Guidelines for the Treatment […]